Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of CYP3A5 and ABCB1 genotype on pharmacokinetics of twice-daily Prograf and once-daily Advagraf in renal transplant recipients
2009-013461-25Phase 4Completed
- Sponsor
- St George's, University of London
- Start
- Mar 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant and Kidney allograft status (RTx), sponsored by St George's, University of London. Primary endpoint: Tacrolimus AUC by CYP3A5 and ABCB1 genotype. Started Mar 2010; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplantKidney allograft status (RTx)
Beyond the preview
Go deeper on 2009-013461-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013461-25.